Asia is expected to lead the global propylene industry capacity additions with a share of 67% by 2030 by gaining capacity from new-build and expansion projects between 2023 and 2030, according to GlobalData, a leading data and analytics company.
Asia is expected to lead the global propylene industry capacity additions with a share of 67% by 2030 by gaining capacity from new-build and expansion projects between 2023 and 2030, according to GlobalData, a leading data and analytics company.
Linerless labels are not a new technology, but they have gained signi cant interest and use in the past eight years. AWArenessTM Report Linerless Labeling 2023 is AWA’s eighth report dedicated to linerless label technology and markets. It provides an update on new developments, growth areas, and applications for linerless labels.
There are over 300 companies globally in this industry, which includes both many of the largest pulp and paper companies, as well as very small companies operating one paper mill, and with just one small paper machine.
With a global growth of 1.5% in 2022 and a CAGR of 2% (2022-2025). As a result of COVID-19 and subsequent supply chain disruptions, many paper producers have had to face shortages in the supply chain, leading to increased prices in the paper market.
The 9th drupa Global Trends Report, to be published in November 2023, is a clear statement of increasing confidence across almost all regions and markets. Printers and suppliers alike forecast it will be even better next year; good for drupa 2024.
The findings come from the 9th Global Trends in-depth survey, run this spring by Printfuture (UK) and Wissler (CH), when over 600 printers and suppliers from the drupa Expert Panel of senior decision makers.
AWA forecast that the volume will grow by 3.6% CAGR from 2022-2025. The volume and growth in pressure-sensitive adhesive is driven principally by end user market growth in the main markets of tapes, labelstock, hygiene, graphic films and medical.
Most economists expect the global economy to weaken in the coming year, as the world grapples with political and financial volatility.
Almost six in 10 believe the economic outlook will undermine progress towards meeting the UN Sustainable Development Goals, with 74% saying geopolitical tensions will have the same effect.
Experts warn that developing countries will face an increasing trade-off between development and climate action.
Manufacturers could be at growing risk of food fraud if they do not take the correct precautions when selecting new suppliers, according to leading global assurance partner, LRQA.
Growth outlook has strengthened in all regions but chief economists divided on likelihood of a global recession in 2023
Experts do not see recent bank failures as signs of systemic vulnerability, although further turbulence may be ahead
Experts concerned about trade-off between managing inflation and maintaining financial stability, with 76% anticipating central banks to struggle to bring down inflation
Industrial policy is increasingly widespread and could further restructure global supply chains
Cube 2026 - Forecasts, 7th Edition
Print output for wide-format and other signage applications are recovering from a downturn at the beginning of the decade. The outlook is still challenging however, as new priorities are established in printed advertising, point-of-sale (PoS) signage, posters, decals, and vehicle graphics.
Labeling and product decoration are critical to the packaging industry, combining the essential information to identify a product with the sales enhancement properties of branding and on-shelf visibility. The status of this market is documented in the newly-published 17th edition of AWA Labeling and Product Decoration Annual Review 2023.
Asia is set to lead the global polypropylene industry capacity additions accounting for a share of 72% by 2027, with the addition of capacities from new-build and expansion projects between 2023 and 2027, says GlobalData, a leading data and analytics company.
Pharma manufacturers will be challenged by the effects of high inflation and declining FDA drug approvals in 2023. Pharmaceutical companies have a high tendency to outsource the finished dose manufacture of new molecular entities (NME).